Castle Biosciences earns multiple Top Workplaces awards, highlighting its strong employee culture and commitment to innovation and support.
Quiver AI Summary
Castle Biosciences, Inc. has achieved multiple accolades in the 2025 Top Workplaces program, including its third consecutive national Healthcare Industry Top Workplaces award, ranking third in its size category, and a fourth consecutive regional Arizona Top Workplaces award. The company has also been recognized for Culture Excellence in various categories, such as Innovation and Work-Life Flexibility, based on anonymous employee feedback. President and CEO Derek Maetzold emphasized the importance of their people-first culture, which fosters innovation and employee engagement. Castle Biosciences aims to improve health through its diagnostic tests and is committed to transforming disease management, with a strong focus on patient care and support for employees.
Potential Positives
- Castle Biosciences received multiple prestigious awards, including a third consecutive national Healthcare Industry Top Workplaces award, which underscores its competitive standing and reputation in the healthcare sector.
- The company was recognized for its strong workplace culture through consecutive national Top Workplaces Culture Excellence awards in key areas like Innovation, Work-Life Flexibility, and Leadership, highlighting its effective employee engagement and satisfaction.
- The awards are based on anonymous employee feedback, which validates Castle's commitment to a people-first culture, fostering an environment that promotes innovation and productivity.
Potential Negatives
- Despite receiving multiple workplace awards, the press release does not provide any concrete details regarding employee retention rates or satisfaction metrics, which could raise questions about the company's ability to maintain its accolades.
- The focus on awards may be perceived as a way to divert attention from other potential issues within the company, such as financial performance or market competition.
- The emphasis on a "people-first culture" may suggest that previous workplace issues required corrective measures, hinting at a potential history of employee dissatisfaction or turnover that was not fully addressed.
FAQ
What awards has Castle Biosciences received in 2025?
Castle Biosciences earned multiple awards, including national and regional Top Workplaces recognitions and Culture Excellence awards for various categories.
How many consecutive years has Castle Biosciences won the Top Workplaces award?
Castle Biosciences has won the Top Workplaces award for three consecutive years at the national level and four years at the regional level.
What is the purpose of the Top Workplaces awards?
The Top Workplaces awards recognize organizations that have built exceptional workplace cultures based on employee feedback collected anonymously through surveys.
What aspects of workplace culture did Castle excel in?
Castle excelled in Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership, and Purpose & Values as highlighted by the Culture Excellence awards.
What is the mission of Castle Biosciences?
Castle Biosciences aims to improve health through innovative tests that guide patient care while keeping people first across all stakeholders.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CSTL Insider Trading Activity
$CSTL insiders have traded $CSTL stock on the open market 47 times in the past 6 months. Of those trades, 0 have been purchases and 47 have been sales.
Here’s a breakdown of recent trading of $CSTL stock by insiders over the last 6 months:
- DEREK J MAETZOLD (Pres. & Chief Exec. Officer) has made 0 purchases and 43 sales selling 63,041 shares for an estimated $1,279,345.
- DANIEL BRADBURY has made 0 purchases and 3 sales selling 7,867 shares for an estimated $221,636.
- FRANK STOKES (Chief Financial Officer) sold 8,046 shares for an estimated $214,828
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CSTL Hedge Fund Activity
We have seen 103 institutional investors add shares of $CSTL stock to their portfolio, and 96 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WASATCH ADVISORS LP removed 797,633 shares (-44.4%) from their portfolio in Q1 2025, for an estimated $15,968,612
- UBS GROUP AG removed 763,841 shares (-94.0%) from their portfolio in Q1 2025, for an estimated $15,292,096
- SCHRODER INVESTMENT MANAGEMENT GROUP added 597,089 shares (+inf%) to their portfolio in Q1 2025, for an estimated $11,953,721
- CITADEL ADVISORS LLC removed 576,130 shares (-69.0%) from their portfolio in Q1 2025, for an estimated $11,534,122
- PARK WEST ASSET MANAGEMENT LLC added 556,485 shares (+inf%) to their portfolio in Q1 2025, for an estimated $11,140,829
- PORTOLAN CAPITAL MANAGEMENT, LLC added 488,644 shares (+62.9%) to their portfolio in Q1 2025, for an estimated $9,782,652
- BELLEVUE GROUP AG removed 444,879 shares (-59.6%) from their portfolio in Q1 2025, for an estimated $8,906,477
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CSTL Analyst Ratings
Wall Street analysts have issued reports on $CSTL in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Scotiabank issued a "Sector Outperform" rating on 05/21/2025
- Lake Street issued a "Buy" rating on 05/06/2025
- Canaccord Genuity issued a "Buy" rating on 05/06/2025
- Baird issued a "Outperform" rating on 02/28/2025
To track analyst ratings and price targets for $CSTL, check out Quiver Quantitative's $CSTL forecast page.
$CSTL Price Targets
Multiple analysts have issued price targets for $CSTL recently. We have seen 4 analysts offer price targets for $CSTL in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- Sung Ji Nam from Scotiabank set a target price of $40.0 on 05/21/2025
- Thomas Flaten from Lake Street set a target price of $35.0 on 05/06/2025
- Kyle Mikson from Canaccord Genuity set a target price of $37.0 on 05/06/2025
- Catherine Ramsey from Baird set a target price of $37.0 on 02/28/2025
Full Release
FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces award, with Castle ranking third among other recognized companies in its size bracket; a fourth consecutive regional Arizona Top Workplaces award from AZ Central ; and consecutive national Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values.
“Being recognized as a Top Workplace, year after year, demonstrates the incredible strength of our Castle team and commitment to our shared mission to improve health through innovative tests that guide patient care,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “These employee-driven honors affirm that our people-first culture isn't just a philosophy, but a catalyst that helps fuel our innovation and impact.”
Top Workplaces awards recognize organizations that have built exceptional workplace cultures, with regional and industry awards celebrating employers of choice within specific areas, and culture excellence awards highlighting organizations that excel in particular aspects of workplace culture. Award designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey measures the workplace experience and various culture themes that are indicative of successful organizations, such as employees feeling “fairly valued,” “engaged,” and “respected and supported.”
Castle’s receipt of the Top Workplaces Culture Excellence awards listed below underscores its strong, people-first culture and provides distinction in the following areas:
- Innovation (2022-2025) , for embedding innovation into its culture and creating an environment where new ideas come from all employees.
- Work-Life Flexibility (2023-2025) , for building a culture that enables employees to meet the demands of their personal lives while maintaining high performance.
- Compensation & Benefits (2022-2025) , for providing employees not only with material rewards but also with appreciation for their work.
- Leadership (2022-2025) , for organizational leaders who inspire confidence in their employees and in the direction of the company.
-
Purpose & Values (2022-2025)
, for successfully communicating the company mission and integrating those aspirations into the culture.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn , Facebook , X and Instagram .
DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
[email protected]
Media Contact:
Allison Marshall
[email protected]
